Connect with others who understand.

Sign up Log in
Resources
About MyLungCancerTeam
Powered By
See answer
See answer

Wearable Device Approved To Treat Advanced NSCLC

Written by Ted Samson
Posted on November 6, 2024

The U.S. Food and Drug Administration (FDA) has approved Optune Lua, a portable device that delivers tumor treating fields (TTFields) to help treat metastatic (advanced) non-small cell lung cancer (NSCLC) in adults who have not responded to platinum-based treatments. Worn on the body, Optune Lua produces alternating electric fields that disrupt the division of cancer cells, leading to their death. It’s used in combination with medication.

In clinical trials, Optune Lua was combined with PD-1/PD-L1 inhibitors or docetaxel. Results showed median overall survival was extended from 9.9 months to 13.2 months compared to drug treatments alone. Side effects, primarily skin irritation under the device, were generally mild to moderate, though some participants experienced more severe reactions.

A Novel Option for Advanced NSCLC Care

Optune Lua is a wearable device that emits TTFields to prevent cancer cells from multiplying. The device includes transducer arrays that are placed on the chest to deliver TTFields directly to the tumor site, along with a portable battery pack and a connection cable. (Novocure)

As the first device approved specifically for metastatic NSCLC, Optune Lua offers a unique approach that may improve survival without adding side effects that occur with traditional chemotherapy and immunotherapy. It can be used with existing treatments. People with advanced NSCLC can discuss with their health care providers whether Optune Lua could be an effective addition to their treatment strategy.

Learn about eight other recent advances in lung cancer treatment.

Find Your Team

On MyLungCancerTeam, the social network for people living with lung cancer and their loved ones, members come together to ask questions, give advice, and share their stories with others who understand life with lung cancer.

Would you try this type of device? Share your tips and experiences in a comment below, start a conversation on your Activities page, or find like-minded people in Groups.

Ted Samson is a copy editor at MyHealthTeam. Learn more about him here.

A MyLungCancerTeam Subscriber

This is wonderful news I Pray it has great success.

November 12
All updates must be accompanied by text or a picture.

We'd love to hear from you! Please share your name and email to post and read comments.

You'll also get the latest articles directly to your inbox.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service.
Privacy Policy
All updates must be accompanied by text or a picture.

Subscribe now to ask your question, get answers, and stay up to date on the latest articles.

Get updates directly to your inbox.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service.
Privacy Policy

Thank you for subscribing!

Become a member to get even more: